Equities

Faron Pharmaceuticals Oy

Faron Pharmaceuticals Oy

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (GBX)216.00
  • Today's Change-8.00 / -3.57%
  • Shares traded7.79k
  • 1 Year change-21.21%
  • Beta-0.1745
Data delayed at least 20 minutes, as of Sep 19 2024 16:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 12-Sep-24
Select bar for recommendation details.
Recommendations12-Sep-24
Buy0
Outperform2
Hold0
Sell0
Strong Sell1

Share price forecast in EUR

The 4 analysts offering 12 month price targets for Faron Pharmaceuticals Oy have a median target of 159.88, with a high estimate of 235.62 and a low estimate of 67.32. The median estimate represents a -25.98% decrease from the last price of 216.00.
High9.1%235.62
Med-26.0%159.88
Low-68.8%67.32

Earnings history & estimates in EUR

Faron Pharmaceuticals Oy reported annual 2023 losses of -0.337 per share on Mar 13, 2024.
Average growth rate-12.35%
More ▼

Revenue history & estimates in EUR

Faron Pharmaceuticals Oy did not report revenues for the full year 2023. However, during the prior year the company reported revenues of 0.00.
Average growth rate0.00%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.